Comparing two types of dialyzers for ESKD patients with sepsis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study compares the efficacy of super high-flux dialyzers to high-flux dialyzers in patients with end-stage kidney disease (ESKD) who are experiencing sepsis. It is an open-label, single-center, randomized control trial that aims to determine if the super high-flux dialyzer can improve mortality rates and outcomes in these patients. Participants will be randomly assigned to one of the two dialyzer groups, with a focus on those exhibiting high levels of interleukin-6. The primary endpoint of the study is mortality within 28 days of treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ESKD patients who have sepsis condition with high interleukin-6 (IL-6 \> 50 pg/ml)

Exclusion Criteria:

* Patients who needed dialysis with continuous kidney replacement therapy, vulnerable patient, include pregnant woman, patient who expected to pass away within the 24 hours.
* Patients who have the history of allergic dialyzer reaction to dialyzer which used in this trial.

Where it's running

• Navamindhradhiraj university
  Dusit, Bangkok, Thailand Recruiting

Study contacts

• Principal investigator: Punnawit Laungchuaychok, MD — Navamindradhiraj University
• Study coordinator: Punnawit Laungchuaychok, MD
• Email: punnawit@nmu.ac.th
• Phone: 022443000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care

  This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.

  Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07922213

• Early detection of sepsis-related blood clotting problems in severe burn patients

  This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.

  Recruiting Center for Traumatology and Major Burns, Ben Arous · Tunis · NCT07914205

• Neutrophil EMR3 as a biomarker for sepsis in ICU patients

  Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07896018

• Thymalfasin added to standard care for adults with sepsis and immune dysfunction

  This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07866118

• Multicenter group study of sepsis and ARDS in China

  This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.

  Recruiting at 24 sites Shanghai Zhongshan Hospital · Xiamen, Fujian and 23 other locations · NCT07863908

• Non-invasive hemodynamic guidance for sepsis care on medical wards

  This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.

  Recruiting at 2 sites Regione del Veneto - AULSS n. 7 Pedemontana · Pisa, Pisa and 1 other locations · NCT07863323

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.